Earlier we have reported on a patent appication related to HPBCD treatment in Alzheimer’s disease based on the invention of Dr. Tsai’s group at MIT:
Now, the research has been reported also by journal Nature on 16 November 2022, (Blanchard, J.W., Akay, L.A., Davila-Velderrain, J. et al. APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature (2022). https://doi.org/10.1038/s41586-022-05439-w), which is at the time being open access, through this link:
The main conclusion of the research:
The team treated some APOE4-expressing mice (APOE4 is the strongest risk factor gene for Alzheimer’s disease) with cyclodextrin, left others untreated, and subjected them all to two different memory tests. The cyclodextrin-treated mice performed both tests significantly better, suggesting an association between improved myelination and improved cognition.
Based on these research data a clear picture is emerging in which intervening to correct specific lipid dysregulations by cell type could potentially help counteract APOE4’s contributions to Alzheimer’s pathology.